A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
This study, called ICONIC-ADVANCE 2, is looking at a new medicine for moderate to severe plaque psoriasis named JNJ-77242113. Psoriasis is a skin condition that causes red, scaly patches. The study aims to find out how well this new medicine works compared to a 'placebo' (a dummy treatment without any active medicine) and another existing medicine called deucravacitinib. Participants will be carefully monitored throughout the study to see if their psoriasis improves and to check for any side effects. The overall goal is to find more effective ways to help people manage their plaque psoriasis.
At a glance
What is this study about?
Imagine you have moderate to severe plaque psoriasis, a condition that causes red, scaly patches on your skin. This study, called ICONIC-ADVANCE 2, is looking for better ways to treat it. Researchers are testing a new medicine, which for now is just known by its code name, JNJ-77242113. They want to see if this new medicine can help improve your skin more effectively than current options.
To do this, some people in the study will receive the new medicine, while others might get a 'placebo' – this looks exactly like the new medicine but doesn't contain any active drug. This helps scientists truly understand if the new medicine is having an effect, beyond what might happen naturally or from simply receiving a treatment. Another group might receive an existing medicine called deucravacitinib, which is already used to treat psoriasis, to see how the new medicine compares.
The main goal is to find out if JNJ-77242113 is a good and safe treatment option for people living with plaque psoriasis. By comparing it to both a dummy treatment and an existing medicine, the researchers hope to understand its benefits and any possible side effects, ultimately working towards improving treatments available for people like you.
Key takeaways
- This study is testing a brand-new medicine for skin psoriasis.
- It aims to see if the new medicine works better than current options or a dummy treatment.
- You must have moderate to severe plaque psoriasis to be eligible.
- Participation involves clinic visits, taking study medicine, and health checks.
- You might receive the new medicine, an existing one, or a placebo.
- You can stop participating in the study at any point.
Who may be eligible?
To join this study, you generally need to be 18 years or older and have been diagnosed with plaque psoriasis for at least 26 weeks (about six months). Your psoriasis needs to cover at least 10% of your body and be considered moderate to severe by the doctors. This means your psoriasis patches are quite noticeable and affect your daily life.
There are also some reasons why you might not be able to join. For example, if you have other types of psoriasis (like erythrodermic or pustular psoriasis), or if your psoriasis was triggered by a specific medicine. People with serious kidney, liver, heart, or other severe health problems are usually not able to take part. Also, if you've recently had a major surgery or plan to have one during the study, you might not be eligible. They'll also check if you have any known allergies to the medicines being tested.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you had plaque psoriasis for at least six months?
- Does your psoriasis cover a fair amount of your body (at least 10%)?
- Has your doctor said your psoriasis is moderate to severe?
- Are you a candidate for light therapy or other systemic (whole-body) treatments for psoriasis?
- Do you have any serious ongoing health problems with your kidneys, heart, or other major organs?
What does participation involve?
This study involves taking either the new medicine (JNJ-77242113), a dummy treatment (placebo), or an existing medicine (deucravacitinib). These would likely be given as tablets or injections, but the full details would be explained. You would have regular visits to the clinic to see the study doctors and nurses. During these visits, they would check your psoriasis, ask how you’re feeling, and carry out some tests, like blood tests, to see how you are responding to the treatment and to monitor your health. You would also have check-ups for any side effects. The total length of your participation would be explained by the study team, and it would involve ongoing assessments and follow-up until the study concludes.
Potential risks and benefits
Locations (128)
- Alliance Dermatology and MOHS Center P CVerified postcodePhoenix, United States
- California Dermatology & Clinical Research InstituteVerified postcodeEncinitas, United States
- T Joseph Raoof Md IncVerified postcodeEncino, United States
- UCSF FresnoVerified postcodeFresno, United States
- University of California Los Angeles - Division of DermatologyVerified postcodeLos Angeles, United States
- Wallace Medical Group, IncVerified postcodeLos Angeles, United States
- Dermatologist Medical Group of North County, Inc.Verified postcodeOceanside, United States
- Miami Dermatology And Laser InstituteVerified postcodeMiami, United States
- Bioclinical Research Alliance Inc.Verified postcodeMiami, United States
- Forcare Clinical Research IncVerified postcodeTampa, United States
- Southeast Dermatology SpecialistsVerified postcodeDouglasville, United States
- Arlington DermatologyVerified postcodeRolling Meadows, United States
Common questions
What is plaque psoriasis?
Plaque psoriasis is a common skin condition that causes thick, red patches covered with silvery scales, which can be itchy or sore.
What is a 'placebo'?
A 'placebo' is a dummy treatment that looks exactly like the real medicine but contains no active drug. It helps researchers see if the actual medicine is truly effective.
Will I know which treatment I'm getting?
Often in these types of studies, participants don't know if they are receiving the new medicine, the existing medicine, or the placebo. This is to ensure the results are fair and unbiased.
How long will the study last?
The full duration of your participation in the study will be discussed with you by the study team if you are eligible and interested.
Is JNJ-77242113 a new medicine?
Yes, JNJ-77242113 is a new medicine currently being investigated for the treatment of plaque psoriasis.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.